Nicotinic Receptor Levels After Stopping Smoking

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

March 31, 2012

Study Completion Date

December 31, 2012

Conditions
Nicotine Addiction
Interventions
DRUG

2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine

"The study will be performed using an Investigational New Drug (IND) Application for the 2-\[18F\]FA radioligand. The 2-\[18F\]FA radiotracer allows us to measure nicotine receptors. The PET imaging technique used at these sessions allows us to measure the amount of light that 2-\[18F\]FA gives off in different regions of the brain, we can estimate how many nicotine receptors are in that region.~2-\[18F\]FA (radiotracer) is investigational, which means it is not approved by the United States Food and Drug Administration (FDA) for the way that it is being used in this research study. For this reason, we have received approval for all procedures in the current study including the use of 2-\[18F\]FA from the FDA."

Trial Locations (1)

19104

Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Pennsylvania

OTHER